AIV007 eye injection for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new eye injection called AIV007 to see if it can safely treat wet age-related macular degeneration (AMD). It's for people who have already had treatment that worked before, and it might offer a different way to deliver the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have wet (neovascular) age-related macular degeneration.
- You have been treated before (like with eye injections) and it helped.
- Your vision in the study eye is not too poor—at least 20/200 or better.
- The disease is still active in your eye (based on a scan).
- Your eye pressure is well controlled.
- You have not had certain eye surgeries in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new eye drop treatment for people with wet age-related macular degeneration (AMD) who have already been treated with standard injections. The goal is to see if this new treatment can help maintain or improve vision and reduce the need for injections.
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
Hear when a new Neovascular (Wet) Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.